Literature DB >> 12168699

Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library.

Natalia G Karasseva1, Vladislav V Glinsky, Ning X Chen, Ravichandra Komatireddy, Thomas P Quinn.   

Abstract

The ErbB-2 receptor, a member of the tyrosine kinase type 1 family of receptors, has been implicated in many human malignancies. The overexpression of ErbB-2 in cancer cells as well as its extracellular accessibility makes it an attractive target for the development of tumor-specific agents. In this study, random peptide bacteriophage display technology was employed to identify peptides that bound the extracellular domain of human ErbB-2. The peptide KCCYSL, most frequently occurring in the affinity-selected phage population, was chemically synthesized and characterized for its binding activities to ErbB-2. The synthetic peptide exhibited high specificity for ErbB-2 and an equilibrium dissociation constant of 30 microM. Peptide binding to ErbB-2 positive human breast and prostate carcinoma cells was visualized in direct cell binding assays. In conclusion, the peptide KCCYSL has the potential to be developed into a cancer imaging or therapeutic agent targeting malignant cells overexpressing the ErbB-2 receptor.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12168699     DOI: 10.1023/a:1019749504418

Source DB:  PubMed          Journal:  J Protein Chem        ISSN: 0277-8033


  31 in total

1.  Development of a peptide-drug conjugate for prostate cancer therapy.

Authors:  Wanyi Tai; Ravi S Shukla; Bin Qin; Benyi Li; Kun Cheng
Journal:  Mol Pharm       Date:  2011-05-03       Impact factor: 4.939

2.  In-labeled KCCYSL peptide as an imaging probe for ErbB-2-expressing ovarian carcinomas.

Authors:  Susan L Deutscher; Said D Figueroa; Senthil R Kumar
Journal:  J Labelled Comp Radiopharm       Date:  2009-12-01       Impact factor: 1.921

Review 3.  Combinatorial peptide libraries: mining for cell-binding peptides.

Authors:  Bethany Powell Gray; Kathlynn C Brown
Journal:  Chem Rev       Date:  2013-12-03       Impact factor: 60.622

4.  Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide.

Authors:  Benjamin M Larimer; Nicholas Phelan; Eric Wehrenberg-Klee; Umar Mahmood
Journal:  Mol Imaging Biol       Date:  2018-04       Impact factor: 3.488

Review 5.  High-Throughput Approaches to the Development of Molecular Imaging Agents.

Authors:  Lina Y Hu; Kimberly A Kelly; Julie L Sutcliffe
Journal:  Mol Imaging Biol       Date:  2017-04       Impact factor: 3.488

6.  In vivo phage display selection of an ovarian cancer targeting peptide for SPECT/CT imaging.

Authors:  Mette Soendergaard; Jessica R Newton-Northup; Susan L Deutscher
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

7.  In vivo bacteriophage peptide display to tailor pharmacokinetics of biological nanoparticles.

Authors:  Jessica R Newton-Northup; Marie T Dickerson; Senthil R Kumar; George P Smith; Thomas P Quinn; Susan L Deutscher
Journal:  Mol Imaging Biol       Date:  2014-12       Impact factor: 3.488

8.  Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer.

Authors:  Benjamin M Larimer; Susan L Deutscher
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-08-15

9.  Identification of a LNCaP-specific binding peptide using phage display.

Authors:  Bin Qin; Wanyi Tai; Ravi S Shukla; Kun Cheng
Journal:  Pharm Res       Date:  2011-05-25       Impact factor: 4.200

10.  Affinity maturation of an ERBB2-targeted SPECT imaging peptide by in vivo phage display.

Authors:  Benjamin M Larimer; William D Thomas; George P Smith; Susan L Deutscher
Journal:  Mol Imaging Biol       Date:  2014-08       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.